Article
Oncology
Patrick Schoffski, Jean -Pascal Machiels, Sylvie Rottey, Behbood Sadrolhefazi, Hanny Musa, Kristell Marzin, Ahmad Awada
Summary: BI 894999, a novel oral BET inhibitor, has shown potent antitumour activity in preclinical studies.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Jianming Xu, Jiuwei Cui, Haiping Jiang, Yan Zeng, Xiuyu Cong
Summary: This study determined the MTD, RP2D, pharmacokinetics, safety, and preliminary efficacy of EVER4010001 plus pembrolizumab in patients with advanced solid tumors. The results showed that 80 mg BID was the MTD and RP2D for EVER4010001 plus pembrolizumab.
Article
Oncology
Laura Vidal, Ivan Victoria, Lydia Gaba, Marta Gil Martin, Merce Brunet, Helena Colom, Marc Cortal, Mariana Gomez-Ferreria, Marc Yeste-Velasco, Antonio Perez, Jordi Rodon, Davendra P. S. Sohal, Jose Miguel Lizcano, Carles Domenech, Jose Alfon, Pere Gascon
Summary: ABTL0812 is a safe and tolerable drug that allows long-term oral dosing. The RP2D of 1300 mg three times a day was determined according to PK/PD modeling, and preliminary antitumor efficacy was observed.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Jeffrey M. Clarke, Jyoti D. Patel, Francisco Robert, Ebenezer A. Kio, Eddie Thara, D. Ross Camidge, Martin Dunbar, Silpa Nuthalapati, Minh H. Dinh, Bruce A. Bach
Summary: The study demonstrated the tolerability and efficacy of the quadruple combination therapy of veliparib with nivolumab and platinum doublet chemotherapy in patients with advanced/metastatic NSCLC with promising antitumor activity. This four-drug therapy showed no evidence of drug-drug interaction and could be a potential treatment option for NSCLC patients.
Article
Oncology
Alexandra Leary, Ana Oaknin, Jose Manuel Trigo, Victor Moreno, Jean-Pierre Delord, Valentina Boni, Irene Brana, Cristian Fernandez, Carmen Kahatt, Antonio Nieto, Martin Cullell-Young, Ali Zeaiter, Vivek Subbiah
Summary: Lurbinectedin is an approved drug for the treatment of metastatic small cell lung cancer. This study analyzes safety data from various solid tumors treated with Lurbinectedin, and confirms its manageable safety profile in patients with advanced solid tumors.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
David M. Loeb, Ji Won Lee, Daniel A. Morgenstern, Yvan Samson, Anne Uyttebroeck, Chuhl Joo Lyu, An Van Damme, Karsten Nysom, Margaret E. Macy, Alexandra P. Zorzi, Julia Xiong, Petra Pollert, Ingrid Joerg, Yulia Vugmeyster, Mary Ruisi, Hyoung Jin Kang
Summary: In paediatric patients with refractory/relapsed solid tumours, avelumab monotherapy showed a safety profile consistent with previous adult studies, but clinical benefits were limited.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Amita Patnaik, Erika Hamilton, Yan Xing, Drew W. Rasco, Lon Smith, Ya-Li Lee, Steven Fang, Jiao Wei, Ai-Min Hui
Summary: This study examines the safety and antitumor efficacy of a novel CDK4/6 inhibitor, FCN-437c, in patients with advanced solid tumors. The results show promising signs of durable tumor response and disease control. Further research is needed to investigate the safety and efficacy of FCN-437c.
Article
Oncology
Bo Gao, Mark Voskoboynik, Adam Cooper, Kate Wilkinson, Siao Hoon, Chih-Yi Hsieh, Suixiong Cai, Ye Edward Tian, Jun Bao, Ning Ma, Chen Wang, Ming Zhang, Baoyue Li, Mingchuan Guo, Ruiyu Zhou, Xiaozhu Wang, Cong Xu, Paul de Souza
Summary: This study evaluated the safety and preliminary efficacy of senaparib in patients with advanced solid tumors. The results showed that senaparib was well tolerated in Australian patients and exhibited encouraging antitumor activity. The recommended phase 2 dose for senaparib was determined to be 100 mg daily.
Article
Oncology
Yi-Long Wu, Ying Cheng, Huajun Chen, Haiyan Tu, Chongrui Xu, Zhen Wang, Ying Liu, Ying Xin, Haizhou Lou, Wei Wang, Kevin Chin, Dandan Li, Di Zhao, Yanfei Gao, Wenping Xu, Hongming Pan
Summary: This study evaluated the efficacy and tolerability of avelumab in Chinese patients. The results showed that avelumab at different doses can stabilize the disease and have partial responses in some patients' tumors.
Article
Oncology
Yi-Long Wu, Ying Cheng, Huajun Chen, Haiyan Tu, Chongrui Xu, Zhen Wang, Ying Liu, Ying Xin, Haizhou Lou, Wei Wang, Kevin Chin, Dandan Li, Di Zhao, Yanfei Gao, Wenping Xu, Hongming Pan
Summary: This study evaluated the safety and pharmacokinetics of avelumab in Chinese patients with advanced solid tumors. The results were consistent with previous global studies, showing some therapeutic effects in Chinese patients.
Article
Oncology
Ye Guo, Weijie Zhang, Jieer Ying, Yanqiao Zhang, Yueyin Pan, Wensheng Qiu, Qingxia Fan, Qi Xu, Yue Ma, Gang Wang, Jing Guo, Weiguo Su, Songhua Fan, Panfeng Tan, Yan Wang, Yang Luo, Hui Zhou, Jin Li
Summary: This study investigated the combination of Fruquintinib and sin-tilimab in patients with advanced solid tumors, including metastatic colorectal cancer. The results showed good safety and tolerability in patients during the dose escalation and dose expansion stages, as well as promising preliminary efficacy.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
C. Mao, D. Ji, Y. Ding, Y. Zhang, W. Song, L. Liu, Y. Wu, L. Song, X. Feng, J. Zhang, J. Cao, N. Xu
Summary: Suvemcitug, a novel humanized rabbit monoclonal antibody against vascular endothelial growth factor, has demonstrated promising antitumor activities and acceptable toxicity profile in pretreated patients with advanced solid tumors and metastatic colorectal cancer.
Article
Oncology
Nehal J. Lakhani, Laura Q. M. Chow, Justin F. Gainor, Patricia LoRusso, Keun-Wook Lee, Hyun Cheol Chung, Jeeyun Lee, Yung-Jue Bang, Frank Stephen Hodi, Won Seog Kim, Rafael Santana-Davila, Philip Fanning, Pierre Squifflet, Feng Jin, Tracy C. Kuo, Hong Wan, Jaume Pons, Sophia S. Randolph, Wells A. Messersmith
Summary: The study evaluated the safety, pharmacokinetics, pharmacodynamics, and anticancer activity of a new drug in patients with solid tumors. The results suggest that this new drug in combination with other medications may have potential therapeutic effects for patients with advanced solid tumors.
Article
Oncology
Christoph Schliemann, Teresa Hemmerle, Andrew F. Berdel, Linus Angenendt, Andrea Kerkhoff, Jan P. Hering, Walter Heindel, Wolfgang Hartmann, Eva Wardelmann, Sant P. Chawla, Filippo de Braud, Georg Lenz, Dario Neri, Torsten Kessler, Wolfgang E. Berdel
Summary: The combination of L19TNF with doxorubicin is safely applicable and induces encouraging tumor remissions in patients with solid tumors, particularly soft tissue sarcomas, as shown in two phase I trials.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Jason D. Lickliter, Mark Voskoboynik, Linda Mileshkin, Hui K. Gan, Ganessan Kichenadasse, Kathy Zhang, Maggie Zhang, Zhiyu Tang, Michael Millward
Summary: Pamiparib was well tolerated with manageable adverse events and showed antitumor activity in patients with epithelial ovarian cancer.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
John H. Strickler, Jonathan M. Loree, Leanne G. Ahronian, Aparna R. Parikh, Donna Niedzwiecki, Allan Andresson, Lima Pereira, Matthew McKinney, W. Michael Korn, Chloe E. Atreya, Kimberly C. Banks, Rebecca J. Nagy, Funda Meric-Bernstam, Richard B. Lanman, AmirAli Talasaz, Igor F. Tsigelny, Ryan B. Corcoran, Scott Kopetz
Editorial Material
Oncology
John H. Strickler
Article
Economics
Christopher N. Graham, Alexandra Christodoulopoulou, Hediyyih N. Knox, Lorenzo Sabatelli, Guy Hechmati, Tamer Garawin, John H. Strickler
JOURNAL OF MEDICAL ECONOMICS
(2018)
Article
Oncology
Jingquan Jia, Michael A. Morse, Rebecca J. Nagy, Richard B. Lanman, John H. Strickler
FRONTIERS IN ONCOLOGY
(2018)
Article
Oncology
C. M. Parseghian, J. M. Loree, V. K. Morris, X. Liu, K. K. Clifton, S. Napolitano, J. T. Henry, A. A. Pereira, E. Vilar, B. Johnson, B. Kee, K. Raghav, A. Dasari, J. Wu, N. Garg, V. M. Raymond, K. C. Banks, A. A. Talasaz, R. B. Lanman, J. H. Strickler, D. S. Hong, R. B. Corcoran, M. J. Overman, S. Kopetz
ANNALS OF ONCOLOGY
(2019)
Review
Oncology
Tanios Bekaii-Saab, Richard Kim, Tae Won Kim, Juan Manuel O'Connor, John H. Strickler, David Malka, Andrea Sartore-Bianchi, Feng Bi, Kensei Yamaguchi, Takayuki Yoshino, Gerald W. Prager
CLINICAL COLORECTAL CANCER
(2019)
Article
Oncology
John H. Strickler, Colin D. Weekes, John Nemunaitis, Ramesh K. Ramanathan, Rebecca S. Heist, Daniel Morgensztern, Eric Angevin, Todd M. Bauer, Huibin Yue, Monica Motwani, Apurvasena Parikh, Edward B. Reilly, Daniel Afar, Louie Naumovski, Karen Kelly
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Article
Gastroenterology & Hepatology
Megan C. Turner, Jeffrey E. Keenan, Christel N. Rushing, Brian C. Gulack, Daniel P. Nussbaum, Ehsan Benrashid, Terry Hyslop, John H. Strickler, Christopher R. Mantyh, John Migaly
JOURNAL OF GASTROINTESTINAL SURGERY
(2019)
Article
Oncology
Zishuo Ian Hu, Johanna C. Bendell, Andrea Bullock, Noelle K. LoConte, Hassan Hatoum, Paul Ritch, Hugo Hool, Joseph W. Leach, James Sanchez, Davendra P. S. Sohal, John Strickler, Ravindranath Patel, Andrea Wang-Gillam, Irfan Firdaus, Kenneth H. Yu, Ann M. Kapoun, Eric Holmgren, Lei Zhou, Jakob Dupont, Vincent Picozzi, Vaibhav Sahai, Eileen M. O'Reilly
Article
Oncology
Jeffrey Melson Clarke, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S. Yousuf Zafar, Michael Morse, Evan Dropkin, Leigh Howard, Margot O'Neill, Christel N. Rushing, Donna Niedzwiecki, Hollie Watson, Emily Bolch, Christy Arrowood, Yingmiao Liu, Andrew B. Nixon, Herbert I. Hurwitz
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2019)
Letter
Oncology
Kanwal Raghav, John H. Strickler
Article
Oncology
Hannah Robinson, Michelle Green, Gauri Radkar, Neal Ready, John Strickler
Summary: This case report highlights the potential of precision oncology approaches in treating rare cancers, such as sinonasal undifferentiated carcinoma, by targeting specific molecular alterations like MET amplification. The successful treatment with the tyrosine kinase inhibitor crizotinib demonstrates the importance of molecularly defined therapies in rare malignancies.
CANCER INVESTIGATION
(2021)
Article
Pharmacology & Pharmacy
Masaya Tachibana, Kyriakos P. Papadopoulos, John H. Strickler, Igor Puzanov, Roohi Gajee, Yibin Wang, Hamim Zahir
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2018)
Review
Oncology
John H. Strickler, Christina Wu, Tanios Bekaii-Saab
CANCER TREATMENT REVIEWS
(2017)